Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2018

Open Access 01-03-2018 | short review

Anti-angiogenic therapies in brain metastases

Authors: Anna S. Berghoff, MD, PhD, Matthias Preusser, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2018

Login to get access

Summary

Brain metastases are a major challenge in modern oncology, as treatment options upon the diagnosis of symptomatic brain metastases are limited. Neo-angiogenesis was identified as a hallmark of brain metastasis development and inhibition using anti-angiogenic therapy might therefore be an experimental promising preventive as well as therapeutic approach. The current review will summarize the current available data on the efficacy of neo-angiogenic therapies in patients with brain metastases.
Literature
1.
Barnholtz-Sloan JS, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.CrossRefPubMed
2.
Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75(1):5–14.CrossRefPubMed
3.
Berghoff AS, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016;1(2):e24.CrossRefPubMedPubMedCentral
4.
Soffietti R, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017;19(2):162–74.CrossRefPubMedPubMedCentral
5.
Preusser M, et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer. 2012;48(18):3439–47.CrossRefPubMed
6.
Kienast Y, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16(1):116–22.CrossRefPubMed
7.
8.
Berghoff AS, et al. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol. 2015;41(2):e41–e55.CrossRefPubMed
9.
Ilhan-Mutlu A, et al. Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther. 2016;15(4):702–10.CrossRefPubMed
10.
11.
Vanhuyse M, et al. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? Bull Cancer. 2012;99(12):100–6.PubMed
12.
Letarte N, Bressler LR, Villano JL. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol. 2013;71(6):1561–5.CrossRefPubMed
13.
Besse B, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269–78.CrossRefPubMed
14.
Socinski MA, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27(31):5255–61.CrossRefPubMed
15.
Bennouna J, et al. Bevacizumab in combination with platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer with or without brain metastases: a French cohort study (EOLE). Oncology. 2017; https://​doi.​org/​10.​1159/​000480702.
16.
Besse B, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015;21(8):1896–903.CrossRefPubMed
17.
Stefanou D, et al. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: focus on patients with brain metastases. Oncol Lett. 2016;12(6):4635–42.CrossRefPubMedPubMedCentral
18.
Labidi SI, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer. 2009;9(2):118–21.CrossRefPubMed
19.
Chevreau C, et al. A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer. 2014;12(1):50–4.CrossRefPubMed
20.
Gore ME, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011;117(3):501–9.CrossRefPubMed
21.
Finkelmeier F, et al. Bevacizumab in combination with chemotherapy for colorectal brain metastasis. J Gastrointest Cancer. 2016;47(1):82–8.CrossRefPubMed
22.
Jeon YS, et al. Palliative resection of metastatic brain tumors previously treated by stereotactic radiosurgery. Brain Tumor Res Treat. 2016;4(2):116–23.CrossRefPubMedPubMedCentral
23.
Glitza IC, et al. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res. 2017;27(6):580–4.CrossRefPubMed
24.
Delishaj D, et al. Bevacizumab for the treatment of radiation-induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017;9(4):273–80.CrossRefPubMedPubMedCentral
25.
Berghoff AS, et al. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case report. Breast Care. 2014;9(2):134–6.CrossRefPubMedPubMedCentral
26.
Vredenburgh JJ, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15(12):1329–34.CrossRefPubMedPubMedCentral
27.
Levy C, et al. REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol. 2014;25(12):2351–6.CrossRefPubMed
28.
Ahluwalia MS, et al. Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1–3 newly diagnosed brain metastases. J Neurooncol. 2015;124(3):485–91.CrossRefPubMed
Metadata
Title
Anti-angiogenic therapies in brain metastases
Authors
Anna S. Berghoff, MD, PhD
Matthias Preusser, MD
Publication date
01-03-2018
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0384-2

Other articles of this Issue 1/2018

memo - Magazine of European Medical Oncology 1/2018 Go to the issue

comment

ESMO 2017—my personal highlights

editorial

memo—publisher’s report 2017

review

Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia

editorial

In need of special care: adolescent and young adult patients with cancer

case report

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity

review

Cell free nucleic acids as diagnostic and prognostic marker in leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits